Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Leerink Swann reduced their FY2017 earnings estimates for shares of Agios Pharmaceuticals in a research report issued to clients and investors on Wednesday. Leerink Swann analyst M. Schmidt now expects that the biopharmaceutical company will post earnings of ($6.44) per share for the year, down from their previous forecast of ($6.36). Leerink Swann has a “Outperform” rating and a $80.00 price objective on the stock. Leerink Swann also issued estimates for Agios Pharmaceuticals’ Q4 2017 earnings at ($1.50) EPS, FY2018 earnings at ($7.38) EPS, FY2019 earnings at ($5.93) EPS and FY2020 earnings at ($4.38) EPS.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, beating the consensus estimate of ($1.78) by $0.19. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The company had revenue of $11.35 million during the quarter, compared to analysts’ expectations of $10.85 million. During the same period in the prior year, the business earned ($1.63) earnings per share. Agios Pharmaceuticals’s revenue for the quarter was up 26.4% compared to the same quarter last year.

COPYRIGHT VIOLATION NOTICE: “Brokers Offer Predictions for Agios Pharmaceuticals, Inc.’s FY2017 Earnings (AGIO)” was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/11/06/brokers-offer-predictions-for-agios-pharmaceuticals-inc-s-fy2017-earnings-agio.html.

Other equities research analysts have also recently issued reports about the company. SunTrust Banks, Inc. reissued a “buy” rating and issued a $80.00 price objective on shares of Agios Pharmaceuticals in a research report on Wednesday, October 4th. J P Morgan Chase & Co reissued a “buy” rating and issued a $76.00 price objective on shares of Agios Pharmaceuticals in a research report on Monday, September 18th. BidaskClub raised Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 13th. Needham & Company LLC increased their price objective on Agios Pharmaceuticals from $54.00 to $72.00 and gave the company a “buy” rating in a research report on Thursday, August 10th. Finally, Canaccord Genuity set a $90.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 8th. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $75.70.

Shares of Agios Pharmaceuticals (NASDAQ:AGIO) opened at $66.49 on Monday. Agios Pharmaceuticals has a 12-month low of $39.24 and a 12-month high of $72.73.

A number of institutional investors have recently added to or reduced their stakes in the business. Alps Advisors Inc. raised its stake in Agios Pharmaceuticals by 9.1% during the third quarter. Alps Advisors Inc. now owns 47,473 shares of the biopharmaceutical company’s stock worth $3,169,000 after acquiring an additional 3,962 shares in the last quarter. Swiss National Bank raised its stake in Agios Pharmaceuticals by 3.3% during the third quarter. Swiss National Bank now owns 68,460 shares of the biopharmaceutical company’s stock worth $4,570,000 after acquiring an additional 2,200 shares in the last quarter. S&CO Inc. acquired a new position in Agios Pharmaceuticals during the third quarter worth $227,000. State Board of Administration of Florida Retirement System raised its stake in Agios Pharmaceuticals by 6.9% during the third quarter. State Board of Administration of Florida Retirement System now owns 54,139 shares of the biopharmaceutical company’s stock worth $3,614,000 after acquiring an additional 3,510 shares in the last quarter. Finally, Pictet Asset Management Ltd. raised its stake in Agios Pharmaceuticals by 198.9% during the third quarter. Pictet Asset Management Ltd. now owns 54,700 shares of the biopharmaceutical company’s stock worth $3,651,000 after acquiring an additional 36,400 shares in the last quarter. Hedge funds and other institutional investors own 93.51% of the company’s stock.

In related news, Director Lewis Clayton Jr. Cantley sold 4,000 shares of the company’s stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $56.85, for a total value of $227,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Scott Biller sold 2,146 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $62.69, for a total value of $134,532.74. The disclosure for this sale can be found here. Insiders sold 178,908 shares of company stock valued at $12,147,719 over the last 90 days. 10.55% of the stock is currently owned by corporate insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.